Cargando…

Low-Dose Tolvaptan for the Treatment of Dilutional Hyponatremia in Cirrhosis: A Case Report and Literature Review

Dilutional hyponatremia is common in decompensated cirrhosis and can be successfully treated by tolvaptan, a vasopressin V2-receptor antagonist. Data were lacking regarding the effects of tolvaptan on cirrhotic patients with a Child-Pugh score of >10 and a serum sodium concentration of <120 mm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Guo, Gao, Hainv
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4208386/ https://www.ncbi.nlm.nih.gov/pubmed/25383228 http://dx.doi.org/10.1155/2014/795261

Ejemplares similares

Tolvaptan and its potential in the treatment of hyponatremia
por: Dixon, Megan B, et al.
Publicado: (2008)

Tolvaptan, hyponatremia, and heart failure
por: Zmily, Hammam D, et al.
Publicado: (2011)

Renoprotection by long‐term low‐dose tolvaptan in patients with heart failure and hyponatremia
por: Oka, Tatsufumi, et al.
Publicado: (2021)

Tolvaptan in the Treatment of Acute Hyponatremia Associated with Acute Kidney Injury
por: Gopinath, Shilpa, et al.
Publicado: (2013)

Unpredictable Nature of Tolvaptan in Treatment of Hypervolemic Hyponatremia: Case Review on Role of Vaptans
por: Malhotra, Ishan, et al.
Publicado: (2014)

Hyponatremia in Cirrhosis and End-Stage Liver Disease: Treatment with the Vasopressin V(2)-Receptor Antagonist Tolvaptan
por: Gaglio, Paul, et al.
Publicado: (2012)

Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia
por: Wang, Shuzhen, et al.
Publicado: (2018)

Association between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients with Ascites and Hyponatremia
por: Hayashi, Manabu, et al.
Publicado: (2018)

Treatment of Hyponatremia with Tolvaptan in a Patient after Neurosurgical Treatment of a Pituitary Tumor: Case Report and Review of Literature
por: Ichimura, Shinya, et al.
Publicado: (2015)

Long-term low-dose tolvaptan treatment in hospitalized male patients aged >90 years with hyponatremia: Report on safety and effectiveness
por: Liu, Yu-hong, et al.
Publicado: (2017)

Edematous Hyponatremia Treated with Tolvaptan in a Patient with Amyotrophic Lateral Sclerosis
por: Kim, Gheun-Ho
Publicado: (2017)

Tolvaptan Treatment in Children with Chronic Hyponatremia due to Inappropriate Antidiuretic Hormone Secretion: A Report of Three Cases
por: Tuli, Gerdi, et al.
Publicado: (2017)

Profound hyponatremia in cirrhosis: a case report
por: Lindsay, Aaron
Publicado: (2010)

Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients
por: Nodari, Savina, et al.
Publicado: (2010)

Tolvaptan for hyponatremia with preserved sodium pool in critically ill patients
por: Umbrello, Michele, et al.
Publicado: (2016)

Management of hyponatremia associated with acute porphyria—proposal for the use of tolvaptan
por: Solares, Isabel, et al.
Publicado: (2020)

Predictors of the Effect of Tolvaptan on the Prognosis of Cirrhosis
por: Iwamoto, Takuya, et al.
Publicado: (2016)

Low-dose tolvaptan PK/PD: comparison of patients with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion to healthy adults
por: Shoaf, Susan E., et al.
Publicado: (2017)

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
por: O’Connor-Byrne, N., et al.
Publicado: (2019)

Tolvaptan Versus Fluid Restriction in the Treatment of Hyponatremia Resulting from SIADH Following Pituitary Surgery
por: Kleindienst, Andrea, et al.
Publicado: (2020)

Effect of tolvaptan on hyponatremia in a dog with syndrome of inappropriate secretion of antidiuretic hormone
por: YAMAMOTO, Hiroka, et al.
Publicado: (2023)

Management Strategies and Outcomes for Hyponatremia in Cirrhosis in the Hyponatremia Registry
por: Sigal, Samuel H., et al.
Publicado: (2018)

Long-term administration of Tolvaptan to patients with decompensated cirrhosis
por: Kanayama, Kengo, et al.
Publicado: (2020)

Post-hepatectomy tolvaptan-induced hypernatremia in a hepatocellular carcinoma patient with cirrhosis: a case report
por: Iida, Hiroya, et al.
Publicado: (2020)

SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan
por: De las Peñas, Ramón, et al.
Publicado: (2015)

Safety and Efficacy of Tolvaptan in Korean Patients with Hyponatremia Caused by the Syndrome of Inappropriate Antidiuretic Hormone
por: Han, Sang Woong, et al.
Publicado: (2018)

Using Tolvaptan to Treat Hyponatremia: Results from a Post-authorization Pharmacovigilance Study
por: Estilo, Alvin, et al.
Publicado: (2021)

Treatment of Cirrhosis-Associated Hyponatremia with Midodrine and Octreotide
por: Patel, Sharad, et al.
Publicado: (2017)

The combined impact of hyponatremia and hematocrit on the risk for 90-day readmission and death in patients with heart failure: dilutional hyponatremia versus depletional hyponatremia
por: Rao, Jiahuan, et al.
Publicado: (2023)

Hyponatremia in Patients with Cirrhosis of the Liver
por: Bernardi, Mauro, et al.
Publicado: (2014)

A rapid and efficient way to manage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptan
por: Petereit, Claudia, et al.
Publicado: (2013)

Severe symptomatic acute hyponatremia in traumatic brain injury responded very rapidly to a single 15 mg dose of oral tolvaptan; a Mayo Clinic Health System hospital experience – need for caution with tolvaptan in younger patients with preserved renal function
por: Onuigbo, Macaulay Amechi Chukwukadibia, et al.
Publicado: (2016)

A case report of rapid-onset hyponatremia induced by low-dose olanzapine
por: Anil, Sethulakshmi Sreevalsam, et al.
Publicado: (2017)

Role of tolvaptan in the management of hyponatremia in patients with lung and other cancers: current data and future perspectives
por: Thajudeen, Bijin, et al.
Publicado: (2016)

Long-term low-dose tolvaptan efficacy and safety in SIADH
por: Bondanelli, Marta, et al.
Publicado: (2023)

Effectiveness of tolvaptan monotherapy and low-dose furosemide/tolvaptan combination therapy for hepatoprotection and diuresis in a rat cirrhotic model
por: Tanabe, Norikazu, et al.
Publicado: (2017)

Hyponatremia – predictor of adverse prognosis in cirrhosis
por: Bengus, A, et al.
Publicado: (2012)

Hyponatremia in Hepatocellular Carcinoma Complicating with Cirrhosis
por: Nishikawa, Hiroki, et al.
Publicado: (2015)

Ascites, refractory ascites and hyponatremia in cirrhosis
por: Fortune, Brett, et al.
Publicado: (2017)

Effect of tolvaptan on acute heart failure with hyponatremia – A randomized, double blind, controlled clinical trial
por: Shanmugam, Elangovan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_c4096d3a0bj1vdpkuftobqaqs6